
Artivion (AORT) Stock Forecast & Price Target
Artivion (AORT) Analyst Ratings
Bulls say
Artivion is expected to have strong revenue growth due to its portfolio of aortic-centric solutions, specifically its Aortic Heart Valve, Mitral Heart Valve, and Aortic Allograft products. The company's growth is also supported by its expansion into international markets, with North America being its largest revenue contributor. Additionally, Artivion's recent product launches and upcoming product approvals, such as its NEXUS platform targeting chronic dissection patients, have the potential to drive further revenue growth and margin improvement. Despite some short-term challenges, AORT shares are now undervalued relative to peers, presenting a potential investment opportunity.
Bears say
Artivion is currently facing temporary issues with an isolated stent graft supplier capacity problem and challenges related to their new AMDS product, but these issues are expected to be resolved with the recent PMA approval and adjustments to payment terms. Their upcoming NEXUS launch and anticipated exit of a competitor in the mechanical valve market will provide a growth driver, and the company has a strong pipeline for future product launches and international expansion. However, they do face risks related to international revenues, tissue preservation services, and quality and regulatory issues.
This aggregate rating is based on analysts' research of Artivion and is not a guaranteed prediction by Public.com or investment advice.
Artivion (AORT) Analyst Forecast & Price Prediction
Start investing in Artivion (AORT)
Order type
Buy in
Order amount
Est. shares
0 shares